UBI results
Diversified revenue mix: Two commercial products on market
• Strong momentum in revenue growth:
Total revenue growth up 76% on pcp to $16.8M
Quarterly Service Fees up 99% on pcp to $12.8M
Coagulation strip sales to Siemens up over 500% on pcp to $1.3M
• Improved financial metrics:
Net loss reduced to $6.6M (down from $9.3M on pcp)
Operating cash flow positive of $1.8M (vs negative $5.4M in pcp)
• Efficient R&D investment:
Total development expense of $19.8M (up 15% on pcp)
Net development expense of $10.5M (up 46% on pcp)
Partner contributions (incl. milestones) of $2.0M (up 12% on pcp
- Forums
- ASX - Day Trading
- Day Trading February 17 - Morning
Day Trading February 17 - Morning, page-245
-
- There are more pages in this discussion • 40 more messages in this thread...
This thread is closed.
You may not reply to this discussion at this time.
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)